City of Hope shared a post on LinkedIn:
“We are proud to congratulate John Carpten, City of Hope’s chief scientific officer, on receiving the Allen Lichter Visionary Leader Award from American Society of Clinical Oncology (ASCO).
Established in 2017, the award recognizes ASCO leaders who have driven meaningful progress in cancer care and inspired the field forward. It’s a recognition that aligns closely with Dr. Carpten’s extraordinary contributions.
His impact as an internationally recognized leader in translational cancer genomics, precision medicine and health disparities research continues to shape the future of cancer care. This honor speaks to the depth of his scientific leadership and the difference it makes for patients everywhere. Most importantly, it reflects his unwavering commitment to ensuring that every person, in every community, has access to leading edge care and scientific discovery.
Please join us in congratulating Dr. Carpten!”
John Carpten, Chief Scientific Officer; Morgan and Helen Chu Director’s Chair of the Beckman Research Institute at City of Hope, shared City of Hope’s post, adding:
“I am deeply honored to receive the American Society of Clinical Oncology (ASCO) Allen Lichter Visionary Leader Award. This recognition reflects the work of so many colleagues, mentors, trainees and community partners who have walked alongside me throughout my career.
At City of Hope, I am privileged to serve as chief scientific officer and to work with teams who are advancing translational cancer genomics, precision medicine and health disparities research in service of patients everywhere.
Together, we’re committed to expanding access to cancer care so more people can benefit from leading edge science and compassionate care.”
More posts featuring City of Hope.